Immutep Limited (IMMP) 10-Year Financial Performance & Capital Metrics

IMMP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.Show more

Revenue $5M +31.3%
EBITDA -$124M -44.4%
Net Income -$61M -43.8%
EPS (Diluted) -0.42 -16.7%
Gross Margin -1117.55% -13.9%
EBITDA Margin -2464.17% -10.0%
Operating Margin -2506.49% -9.3%
Net Margin -1218.02% -9.5%
ROE -36.88% -40.7%
ROIC -176.93% +41.6%
Debt/Equity 0.01 +34.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Sales declining 7.6% over 5 years
✗Shares diluted 21.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.19%

5Y-7.59%

3Y209.35%

TTM54.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-44.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.7%

ROCE

10Y Avg-61.88%

5Y Avg-57.55%

3Y Avg-65.19%

Latest-75.4%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	175.05K	4.22M	2.63M	139.78K	7.49M	3.86M	170.37K	3.51M	3.84M	5.04M
Revenue Growth %	-0.92%	23.12%	-0.38%	-0.95%	52.56%	-0.48%	-0.96%	19.58%	0.1%	0.31%
Cost of Goods Sold+	7.06M	1.7M	9.99M	16.59M	22.47M	17.24M	2.06M	2.06M	41.55M	61.41M
COGS % of Revenue	40.33%	0.4%	3.8%	118.69%	3%	4.46%	12.11%	0.59%	10.81%	12.18%
Gross Profit+	-6.88M	2.52M	-7.36M	-16.45M	-14.99M	-13.37M	-1.89M	1.44M	-37.7M	-56.37M
Gross Margin %	-39.33%	0.6%	-2.8%	-117.69%	-2%	-3.46%	-11.11%	0.41%	-9.81%	-11.18%
Gross Profit Growth %	-4.67%	1.37%	-3.92%	-1.24%	0.09%	0.11%	0.86%	1.76%	-27.11%	-0.49%
Operating Expenses+	61.91M	9.46M	14.82M	19.1M	22.56M	18.3M	32.55M	44.94M	50.4M	70.06M
OpEx % of Revenue	353.69%	2.24%	5.63%	136.66%	3.01%	4.74%	191.04%	12.82%	13.12%	13.89%
Selling, General & Admin	54.45M	4.35M	7.24M	6.13M	6.34M	6.28M	7.21M	14.08M	8.85M	8.64M
SG&A % of Revenue	311.05%	1.03%	2.75%	43.85%	0.85%	1.63%	42.32%	4.02%	2.3%	1.71%
Research & Development	7.06M	7.53M	9.99M	16.59M	20.4M	17.24M	31.34M	28.79M	41.55M	61.41M
R&D % of Revenue	40.33%	1.78%	3.8%	118.69%	2.72%	4.46%	183.96%	8.21%	10.81%	12.18%
Other Operating Expenses	-1.15M	-751.82K	-866.85K	-3.62M	-4.17M	-5.22M	-6M	2.06M	0	0
Operating Income+	-61.47M	-9.35M	-11.69M	-20.42M	-16.02M	-31.68M	-33.94M	-77.69M	-88.1M	-126.42M
Operating Margin %	-351.18%	-2.22%	-4.45%	-146.07%	-2.14%	-8.2%	-199.2%	-22.16%	-22.93%	-25.06%
Operating Income Growth %	-3.42%	0.85%	-0.25%	-0.75%	0.22%	-0.98%	-0.07%	-1.29%	-0.13%	-0.43%
EBITDA+	-59.48M	-7.65M	-9.88M	-18.54M	-13.94M	-29.79M	-32.1M	-75.83M	-86.09M	-124.29M
EBITDA Margin %	-339.79%	-1.81%	-3.76%	-132.62%	-1.86%	-7.71%	-188.41%	-21.63%	-22.41%	-24.64%
EBITDA Growth %	-3.73%	0.87%	-0.29%	-0.88%	0.25%	-1.14%	-0.08%	-1.36%	-0.14%	-0.44%
D&A (Non-Cash Add-back)	1.99M	1.7M	1.81M	1.88M	2.08M	1.89M	1.84M	1.86M	2.01M	2.13M
EBIT	-63.19M	-9.46M	-12.74M	-18.34M	-13.46M	-19.66M	-33.84M	-41.43M	-46.56M	-65.01M
Net Interest Income+	255.84K	0	177.19K	397.28K	189.08K	95.5K	132.09K	918.6K	3.85M	5.25M
Interest Income	264.04K	104.37K	177.19K	397.28K	199.54K	105.33K	224.52K	939K	3.88M	5.25M
Interest Expense	8.2K	0	0	0	10.46K	9.82K	92.43K	20.4K	30.59K	0
Other Income/Expense	2.93M	4.64M	6.61M	2.07M	2.55M	1.77M	1.63M	37.79M	45.39M	64.99M
Pretax Income+	-63.2M	-10.1M	-12.74M	-18.34M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Pretax Margin %	-361.01%	-2.39%	-4.84%	-131.23%	-1.8%	-7.74%	-189.06%	-11.38%	-11.12%	-12.18%
Income Tax+	-1.18M	-737.39K	1.68K	-2.07M	37	33	34	0	0	0
Effective Tax Rate %	0.98%	0.93%	1%	0.89%	1%	1%	1%	1%	1%	1%
Net Income+	-62.02M	-9.37M	-12.75M	-16.27M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Net Margin %	-354.27%	-2.22%	-4.85%	-116.4%	-1.8%	-7.74%	-189.07%	-11.38%	-11.12%	-12.18%
Net Income Growth %	-0.93%	0.85%	-0.36%	-0.28%	0.17%	-1.22%	-0.08%	-0.24%	-0.07%	-0.44%
Net Income (Continuing)	-62.02M	-9.37M	-12.75M	-18.34M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.70	-0.44	-0.48	-0.47	-0.33	-0.49	-0.37	-0.44	-0.36	-0.42
EPS Growth %	-0.35%	0.84%	-0.09%	0.02%	0.3%	-0.48%	0.24%	-0.19%	0.18%	-0.17%
EPS (Basic)	-2.70	-0.44	-0.48	-0.47	-0.33	-0.49	-0.37	-0.44	-0.36	-0.42
Diluted Shares Outstanding	42.69M	42.69M	42.69M	42.69M	40.73M	60.43M	86.23M	90.06M	120.11M	145.58M
Basic Shares Outstanding	42.69M	42.69M	42.69M	42.69M	40.73M	60.43M	86.23M	90.06M	119.99M	145.58M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	21.67M	15.92M	28.64M	23.54M	31.15M	68.42M	90.81M	134.97M	191.35M	149.1M
Cash & Short-Term Investments	20.88M	12.24M	23.48M	16.57M	26.32M	60.13M	80M	123.42M	181.88M	129.69M
Cash Only	20.88M	12.24M	23.48M	16.57M	26.32M	60.13M	80M	123.42M	161.79M	67.41M
Short-Term Investments	0	0	0	0	0	0	0	0	20.09M	62.28M
Accounts Receivable	168.5K	2.19M	3.48M	5.23M	3.39M	6.12M	8.37M	7.97M	7.56M	7.46K
Days Sales Outstanding	351.35	189.71	483.19	13.66K	165.36	578.68	17.94K	830.13	718.1	0.54
Inventory	591.93K	642K	0	0	0	-5.66M	0	0	0	0
Days Inventory Outstanding	30.6	137.71	-	-	-	-	-	-	-	-
Other Current Assets	0	3.08M	0	0	0	6.16M	0	0	0	10.87M
Total Non-Current Assets+	20.88M	19.04M	18.36M	17M	15.45M	13.61M	11.36M	12.48M	10.23M	7.89M
Property, Plant & Equipment	31.5K	24.2K	26.45K	52.95K	250.57K	309.7K	308.08K	468.51K	679.72K	569.48K
Fixed Asset Turnover	5.56x	174.43x	99.45x	2.64x	29.88x	12.47x	0.55x	7.48x	5.65x	8.86x
Goodwill	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K
Intangible Assets	20.74M	18.91M	18.22M	16.84M	15.08M	12.74M	10.44M	9.38M	8.13M	7.09M
Long-Term Investments	18.47M	16.21M	15.62M	0	0	0	0	0	0	0
Other Non-Current Assets	-20.88M	-19.04M	-18.36M	-17M	0	454.19K	495.66K	2.52M	1.31M	116.64K
Total Assets+	42.55M	34.96M	47M	40.54M	46.6M	82.03M	102.17M	147.45M	201.58M	156.98M
Asset Turnover	0.00x	0.12x	0.06x	0.00x	0.16x	0.05x	0.00x	0.02x	0.02x	0.03x
Asset Growth %	0.37%	-0.18%	0.34%	-0.14%	0.15%	0.76%	0.25%	0.44%	0.37%	-0.22%
Total Current Liabilities+	1.47M	2.63M	3.85M	5.3M	3.36M	5.34M	6.41M	9.77M	10.49M	12.76M
Accounts Payable	561.26K	1.14M	1.62M	2.56M	1.64M	1.82M	2.87M	5.45M	3.79M	5.53M
Days Payables Outstanding	29.02	244.26	59.02	56.26	26.63	38.64	506.98	964.49	33.3	32.89
Short-Term Debt	0	0	0	0	0	208.19K	0	0	0	1.1M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	883.08K	1.45M	2.05M	2.5M	1.29M	2.75M	3.02M	354.84K	428.71K	446.95K
Current Ratio	14.72x	6.05x	7.43x	4.44x	9.26x	12.81x	14.16x	13.81x	18.25x	11.69x
Quick Ratio	14.32x	5.80x	7.43x	4.44x	9.26x	13.87x	14.16x	13.81x	18.25x	11.69x
Cash Conversion Cycle	352.93	83.15	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.76M	5.8M	9.62M	10.85M	9.93M	3.42M	1.68M	1.21M	1.57M	589.23K
Long-Term Debt	5.03M	5.78M	6.65M	7.64M	8.79M	2.53M	1.45M	835.45K	960.76K	0
Capital Lease Obligations	0	0	0	0	132.97K	80.11K	107.49K	207.62K	399.41K	314.91K
Deferred Tax Liabilities	694.19K	2.84M	2.73M	0	0	0	0	0	0	0
Other Non-Current Liabilities	737.35K	20.5K	2.98M	3.21M	1.01M	811.88K	117.25K	164.43K	211.01K	274.31K
Total Liabilities	7.24M	8.43M	13.48M	16.15M	13.3M	8.76M	8.09M	10.98M	12.06M	13.35M
Total Debt+	5.03M	5.78M	6.65M	7.64M	9.05M	2.82M	1.73M	1.23M	1.59M	1.63M
Net Debt	-15.85M	-6.46M	-16.83M	-8.93M	-17.27M	-57.31M	-78.26M	-122.19M	-160.2M	-65.78M
Debt / Equity	0.14x	0.22x	0.20x	0.31x	0.27x	0.04x	0.02x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7497.79x	-	-	-	-1531.88x	-3224.10x	-367.17x	-3808.07x	-2879.79x	-
Total Equity+	35.32M	26.53M	33.52M	24.39M	33.3M	73.27M	94.08M	136.47M	189.52M	143.64M
Equity Growth %	0.43%	-0.25%	0.26%	-0.27%	0.37%	1.2%	0.28%	0.45%	0.39%	-0.24%
Book Value per Share	0.83	0.62	0.79	0.57	0.82	1.21	1.09	1.52	1.58	0.99
Total Shareholders' Equity	35.32M	26.53M	33.52M	24.39M	33.3M	73.27M	94.08M	136.47M	189.52M	143.64M
Common Stock	194.53M	195.35M	213.23M	221.09M	242.99M	313.42M	367.41M	446.27M	542.11M	535.07M
Retained Earnings	-222.47M	-231.84M	-244.58M	-262.24M	-275.71M	-274.64M	-302.34M	-339.93M	-382.65M	-444.08M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	63.26M	63.02M	64.87M	65.53M	66.01M	34.49M	29M	30.13M	30.06M	52.65M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-11.31M	-8.51M	-7.78M	-15.29M	-10.84M	-17.64M	-30.23M	-35.88M	-34.82M	-62.05M
Operating CF Margin %	-64.61%	-2.02%	-2.96%	-109.36%	-1.45%	-4.57%	-177.44%	-10.24%	-9.06%	-12.3%
Operating CF Growth %	-0.45%	0.25%	0.09%	-0.97%	0.29%	-0.63%	-0.71%	-0.19%	0.03%	-0.78%
Net Income	-62.02M	-9.37M	-12.75M	-18.34M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Depreciation & Amortization	1.99M	1.7M	1.81M	1.88M	2.08M	2.07M	2.06M	2.06M	2.26M	2.39M
Stock-Based Compensation	49.53M	862.23K	2.26M	1.58M	1.72M	1.7M	1.49M	2M	1.8M	1.16M
Deferred Taxes	826.37K	-218.57K	-9.79M	-5.71M	-6.11M	-7.29M	0	-4.99M	0	0
Other Non-Cash Items	1.15M	751.82K	10.94M	5.65M	4.84M	17.77M	-8.04K	4.17M	379.87K	4.37M
Working Capital Changes	-2.79M	-2.24M	-252.22K	-345.19K	94.16K	-1.99M	-1.56M	764.6K	3.46M	-8.54M
Change in Receivables	-394.92K	-2.03M	-1.24M	-1.76M	1.9M	-2.83M	-2.25M	-1.61M	601.76K	-2.52M
Change in Inventory	1.89M	648.58K	0	0	0	0	813.92K	0	0	0
Change in Payables	-1.49M	1.38M	1.08M	1.4M	-2.13M	1.38M	1.44M	3.27M	0	0
Cash from Investing+	102.58K	-6.64K	-11.89K	-41.43K	-19.35K	-15.6K	-22.91K	-31K	-21.02M	-38.53M
Capital Expenditures	-27.13K	-6.64K	-11.89K	-41.43K	-19.35K	-15.6K	-22.91K	-47K	-932.37K	-45.77K
CapEx % of Revenue	0.15%	0%	0%	0.3%	0%	0%	0.13%	0.01%	0.24%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-6.64K	-11.89K	-41.43K	0	0	0	16K	0	-38.49M
Cash from Financing+	25.72M	-8.53K	18.4M	8.01M	20.48M	52.68M	50.33M	76.04M	95.18M	-525.12K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-283.15K	-8.53K	1.44M	3.14M	-1.47M	9.59M	-2.43M	-3.83M	-4.83M	-254.46K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.34M	-8.51M	-7.79M	-15.33M	-10.86M	-17.66M	-30.25M	-35.93M	-35.75M	-62.1M
FCF Margin %	-64.76%	-2.02%	-2.96%	-109.66%	-1.45%	-4.57%	-177.57%	-10.25%	-9.31%	-12.31%
FCF Growth %	-0.45%	0.25%	0.09%	-0.97%	0.29%	-0.63%	-0.71%	-0.19%	0%	-0.74%
FCF per Share	-0.27	-0.20	-0.18	-0.36	-0.27	-0.29	-0.35	-0.40	-0.30	-0.43
FCF Conversion (FCF/Net Income)	0.18x	0.91x	0.61x	0.94x	0.80x	0.59x	0.94x	0.90x	0.82x	1.01x
Interest Paid	0	0	0	0	0	0	0	0	0	35.55K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-206.69%	-30.29%	-42.45%	-56.19%	-46.69%	-56.12%	-38.5%	-34.61%	-26.21%	-36.88%
Return on Invested Capital (ROIC)	-237.03%	-35.48%	-47.71%	-95.25%	-76.3%	-148.54%	-160.21%	-387.2%	-303.07%	-176.93%
Gross Margin	-3932.82%	59.69%	-279.77%	-11769.34%	-200.18%	-346.22%	-1111.18%	41.19%	-981.42%	-1117.55%
Net Margin	-35426.72%	-221.89%	-484.55%	-11640.01%	-179.9%	-774.12%	-18906.51%	-1138.04%	-1111.87%	-1218.02%
Debt / Equity	0.14x	0.22x	0.20x	0.31x	0.27x	0.04x	0.02x	0.01x	0.01x	0.01x
Interest Coverage	-7497.79x	-	-	-	-1531.88x	-3224.10x	-367.17x	-3808.07x	-2879.79x	-
FCF Conversion	0.18x	0.91x	0.61x	0.94x	0.80x	0.59x	0.94x	0.90x	0.82x	1.01x
Revenue Growth	-91.64%	2311.59%	-37.69%	-94.69%	5255.8%	-48.4%	-95.59%	1957.72%	9.59%	31.28%

Frequently Asked Questions

Growth & Financials

Immutep Limited (IMMP) reported $8.9M in revenue for fiscal year 2025. This represents a 485% increase from $1.5M in 2012.

Immutep Limited (IMMP) grew revenue by 31.3% over the past year. This is strong growth.

Immutep Limited (IMMP) reported a net loss of $104.2M for fiscal year 2025.

Dividend & Returns

Immutep Limited (IMMP) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.

Immutep Limited (IMMP) had negative free cash flow of $97.8M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Immutep Limited (IMMP) 10-Year Financial Performance & Capital Metrics

IMMP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $5M +31.3%
EBITDA -$124M -44.4%
Net Income -$61M -43.8%
EPS (Diluted) -0.42 -16.7%
Gross Margin -1117.55% -13.9%
EBITDA Margin -2464.17% -10.0%
Operating Margin -2506.49% -9.3%
Net Margin -1218.02% -9.5%
ROE -36.88% -40.7%
ROIC -176.93% +41.6%
Debt/Equity 0.01 +34.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Sales declining 7.6% over 5 years
✗Shares diluted 21.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.19%

5Y-7.59%

3Y209.35%

TTM54.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-44.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.7%

ROCE

10Y Avg-61.88%

5Y Avg-57.55%

3Y Avg-65.19%

Latest-75.4%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	175.05K	4.22M	2.63M	139.78K	7.49M	3.86M	170.37K	3.51M	3.84M	5.04M
Revenue Growth %	-0.92%	23.12%	-0.38%	-0.95%	52.56%	-0.48%	-0.96%	19.58%	0.1%	0.31%
Cost of Goods Sold+	7.06M	1.7M	9.99M	16.59M	22.47M	17.24M	2.06M	2.06M	41.55M	61.41M
COGS % of Revenue	40.33%	0.4%	3.8%	118.69%	3%	4.46%	12.11%	0.59%	10.81%	12.18%
Gross Profit+	-6.88M	2.52M	-7.36M	-16.45M	-14.99M	-13.37M	-1.89M	1.44M	-37.7M	-56.37M
Gross Margin %	-39.33%	0.6%	-2.8%	-117.69%	-2%	-3.46%	-11.11%	0.41%	-9.81%	-11.18%
Gross Profit Growth %	-4.67%	1.37%	-3.92%	-1.24%	0.09%	0.11%	0.86%	1.76%	-27.11%	-0.49%
Operating Expenses+	61.91M	9.46M	14.82M	19.1M	22.56M	18.3M	32.55M	44.94M	50.4M	70.06M
OpEx % of Revenue	353.69%	2.24%	5.63%	136.66%	3.01%	4.74%	191.04%	12.82%	13.12%	13.89%
Selling, General & Admin	54.45M	4.35M	7.24M	6.13M	6.34M	6.28M	7.21M	14.08M	8.85M	8.64M
SG&A % of Revenue	311.05%	1.03%	2.75%	43.85%	0.85%	1.63%	42.32%	4.02%	2.3%	1.71%
Research & Development	7.06M	7.53M	9.99M	16.59M	20.4M	17.24M	31.34M	28.79M	41.55M	61.41M
R&D % of Revenue	40.33%	1.78%	3.8%	118.69%	2.72%	4.46%	183.96%	8.21%	10.81%	12.18%
Other Operating Expenses	-1.15M	-751.82K	-866.85K	-3.62M	-4.17M	-5.22M	-6M	2.06M	0	0
Operating Income+	-61.47M	-9.35M	-11.69M	-20.42M	-16.02M	-31.68M	-33.94M	-77.69M	-88.1M	-126.42M
Operating Margin %	-351.18%	-2.22%	-4.45%	-146.07%	-2.14%	-8.2%	-199.2%	-22.16%	-22.93%	-25.06%
Operating Income Growth %	-3.42%	0.85%	-0.25%	-0.75%	0.22%	-0.98%	-0.07%	-1.29%	-0.13%	-0.43%
EBITDA+	-59.48M	-7.65M	-9.88M	-18.54M	-13.94M	-29.79M	-32.1M	-75.83M	-86.09M	-124.29M
EBITDA Margin %	-339.79%	-1.81%	-3.76%	-132.62%	-1.86%	-7.71%	-188.41%	-21.63%	-22.41%	-24.64%
EBITDA Growth %	-3.73%	0.87%	-0.29%	-0.88%	0.25%	-1.14%	-0.08%	-1.36%	-0.14%	-0.44%
D&A (Non-Cash Add-back)	1.99M	1.7M	1.81M	1.88M	2.08M	1.89M	1.84M	1.86M	2.01M	2.13M
EBIT	-63.19M	-9.46M	-12.74M	-18.34M	-13.46M	-19.66M	-33.84M	-41.43M	-46.56M	-65.01M
Net Interest Income+	255.84K	0	177.19K	397.28K	189.08K	95.5K	132.09K	918.6K	3.85M	5.25M
Interest Income	264.04K	104.37K	177.19K	397.28K	199.54K	105.33K	224.52K	939K	3.88M	5.25M
Interest Expense	8.2K	0	0	0	10.46K	9.82K	92.43K	20.4K	30.59K	0
Other Income/Expense	2.93M	4.64M	6.61M	2.07M	2.55M	1.77M	1.63M	37.79M	45.39M	64.99M
Pretax Income+	-63.2M	-10.1M	-12.74M	-18.34M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Pretax Margin %	-361.01%	-2.39%	-4.84%	-131.23%	-1.8%	-7.74%	-189.06%	-11.38%	-11.12%	-12.18%
Income Tax+	-1.18M	-737.39K	1.68K	-2.07M	37	33	34	0	0	0
Effective Tax Rate %	0.98%	0.93%	1%	0.89%	1%	1%	1%	1%	1%	1%
Net Income+	-62.02M	-9.37M	-12.75M	-16.27M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Net Margin %	-354.27%	-2.22%	-4.85%	-116.4%	-1.8%	-7.74%	-189.07%	-11.38%	-11.12%	-12.18%
Net Income Growth %	-0.93%	0.85%	-0.36%	-0.28%	0.17%	-1.22%	-0.08%	-0.24%	-0.07%	-0.44%
Net Income (Continuing)	-62.02M	-9.37M	-12.75M	-18.34M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.70	-0.44	-0.48	-0.47	-0.33	-0.49	-0.37	-0.44	-0.36	-0.42
EPS Growth %	-0.35%	0.84%	-0.09%	0.02%	0.3%	-0.48%	0.24%	-0.19%	0.18%	-0.17%
EPS (Basic)	-2.70	-0.44	-0.48	-0.47	-0.33	-0.49	-0.37	-0.44	-0.36	-0.42
Diluted Shares Outstanding	42.69M	42.69M	42.69M	42.69M	40.73M	60.43M	86.23M	90.06M	120.11M	145.58M
Basic Shares Outstanding	42.69M	42.69M	42.69M	42.69M	40.73M	60.43M	86.23M	90.06M	119.99M	145.58M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	21.67M	15.92M	28.64M	23.54M	31.15M	68.42M	90.81M	134.97M	191.35M	149.1M
Cash & Short-Term Investments	20.88M	12.24M	23.48M	16.57M	26.32M	60.13M	80M	123.42M	181.88M	129.69M
Cash Only	20.88M	12.24M	23.48M	16.57M	26.32M	60.13M	80M	123.42M	161.79M	67.41M
Short-Term Investments	0	0	0	0	0	0	0	0	20.09M	62.28M
Accounts Receivable	168.5K	2.19M	3.48M	5.23M	3.39M	6.12M	8.37M	7.97M	7.56M	7.46K
Days Sales Outstanding	351.35	189.71	483.19	13.66K	165.36	578.68	17.94K	830.13	718.1	0.54
Inventory	591.93K	642K	0	0	0	-5.66M	0	0	0	0
Days Inventory Outstanding	30.6	137.71	-	-	-	-	-	-	-	-
Other Current Assets	0	3.08M	0	0	0	6.16M	0	0	0	10.87M
Total Non-Current Assets+	20.88M	19.04M	18.36M	17M	15.45M	13.61M	11.36M	12.48M	10.23M	7.89M
Property, Plant & Equipment	31.5K	24.2K	26.45K	52.95K	250.57K	309.7K	308.08K	468.51K	679.72K	569.48K
Fixed Asset Turnover	5.56x	174.43x	99.45x	2.64x	29.88x	12.47x	0.55x	7.48x	5.65x	8.86x
Goodwill	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K	109.96K
Intangible Assets	20.74M	18.91M	18.22M	16.84M	15.08M	12.74M	10.44M	9.38M	8.13M	7.09M
Long-Term Investments	18.47M	16.21M	15.62M	0	0	0	0	0	0	0
Other Non-Current Assets	-20.88M	-19.04M	-18.36M	-17M	0	454.19K	495.66K	2.52M	1.31M	116.64K
Total Assets+	42.55M	34.96M	47M	40.54M	46.6M	82.03M	102.17M	147.45M	201.58M	156.98M
Asset Turnover	0.00x	0.12x	0.06x	0.00x	0.16x	0.05x	0.00x	0.02x	0.02x	0.03x
Asset Growth %	0.37%	-0.18%	0.34%	-0.14%	0.15%	0.76%	0.25%	0.44%	0.37%	-0.22%
Total Current Liabilities+	1.47M	2.63M	3.85M	5.3M	3.36M	5.34M	6.41M	9.77M	10.49M	12.76M
Accounts Payable	561.26K	1.14M	1.62M	2.56M	1.64M	1.82M	2.87M	5.45M	3.79M	5.53M
Days Payables Outstanding	29.02	244.26	59.02	56.26	26.63	38.64	506.98	964.49	33.3	32.89
Short-Term Debt	0	0	0	0	0	208.19K	0	0	0	1.1M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	883.08K	1.45M	2.05M	2.5M	1.29M	2.75M	3.02M	354.84K	428.71K	446.95K
Current Ratio	14.72x	6.05x	7.43x	4.44x	9.26x	12.81x	14.16x	13.81x	18.25x	11.69x
Quick Ratio	14.32x	5.80x	7.43x	4.44x	9.26x	13.87x	14.16x	13.81x	18.25x	11.69x
Cash Conversion Cycle	352.93	83.15	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.76M	5.8M	9.62M	10.85M	9.93M	3.42M	1.68M	1.21M	1.57M	589.23K
Long-Term Debt	5.03M	5.78M	6.65M	7.64M	8.79M	2.53M	1.45M	835.45K	960.76K	0
Capital Lease Obligations	0	0	0	0	132.97K	80.11K	107.49K	207.62K	399.41K	314.91K
Deferred Tax Liabilities	694.19K	2.84M	2.73M	0	0	0	0	0	0	0
Other Non-Current Liabilities	737.35K	20.5K	2.98M	3.21M	1.01M	811.88K	117.25K	164.43K	211.01K	274.31K
Total Liabilities	7.24M	8.43M	13.48M	16.15M	13.3M	8.76M	8.09M	10.98M	12.06M	13.35M
Total Debt+	5.03M	5.78M	6.65M	7.64M	9.05M	2.82M	1.73M	1.23M	1.59M	1.63M
Net Debt	-15.85M	-6.46M	-16.83M	-8.93M	-17.27M	-57.31M	-78.26M	-122.19M	-160.2M	-65.78M
Debt / Equity	0.14x	0.22x	0.20x	0.31x	0.27x	0.04x	0.02x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7497.79x	-	-	-	-1531.88x	-3224.10x	-367.17x	-3808.07x	-2879.79x	-
Total Equity+	35.32M	26.53M	33.52M	24.39M	33.3M	73.27M	94.08M	136.47M	189.52M	143.64M
Equity Growth %	0.43%	-0.25%	0.26%	-0.27%	0.37%	1.2%	0.28%	0.45%	0.39%	-0.24%
Book Value per Share	0.83	0.62	0.79	0.57	0.82	1.21	1.09	1.52	1.58	0.99
Total Shareholders' Equity	35.32M	26.53M	33.52M	24.39M	33.3M	73.27M	94.08M	136.47M	189.52M	143.64M
Common Stock	194.53M	195.35M	213.23M	221.09M	242.99M	313.42M	367.41M	446.27M	542.11M	535.07M
Retained Earnings	-222.47M	-231.84M	-244.58M	-262.24M	-275.71M	-274.64M	-302.34M	-339.93M	-382.65M	-444.08M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	63.26M	63.02M	64.87M	65.53M	66.01M	34.49M	29M	30.13M	30.06M	52.65M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-11.31M	-8.51M	-7.78M	-15.29M	-10.84M	-17.64M	-30.23M	-35.88M	-34.82M	-62.05M
Operating CF Margin %	-64.61%	-2.02%	-2.96%	-109.36%	-1.45%	-4.57%	-177.44%	-10.24%	-9.06%	-12.3%
Operating CF Growth %	-0.45%	0.25%	0.09%	-0.97%	0.29%	-0.63%	-0.71%	-0.19%	0.03%	-0.78%
Net Income	-62.02M	-9.37M	-12.75M	-18.34M	-13.47M	-29.9M	-32.21M	-39.9M	-42.72M	-61.43M
Depreciation & Amortization	1.99M	1.7M	1.81M	1.88M	2.08M	2.07M	2.06M	2.06M	2.26M	2.39M
Stock-Based Compensation	49.53M	862.23K	2.26M	1.58M	1.72M	1.7M	1.49M	2M	1.8M	1.16M
Deferred Taxes	826.37K	-218.57K	-9.79M	-5.71M	-6.11M	-7.29M	0	-4.99M	0	0
Other Non-Cash Items	1.15M	751.82K	10.94M	5.65M	4.84M	17.77M	-8.04K	4.17M	379.87K	4.37M
Working Capital Changes	-2.79M	-2.24M	-252.22K	-345.19K	94.16K	-1.99M	-1.56M	764.6K	3.46M	-8.54M
Change in Receivables	-394.92K	-2.03M	-1.24M	-1.76M	1.9M	-2.83M	-2.25M	-1.61M	601.76K	-2.52M
Change in Inventory	1.89M	648.58K	0	0	0	0	813.92K	0	0	0
Change in Payables	-1.49M	1.38M	1.08M	1.4M	-2.13M	1.38M	1.44M	3.27M	0	0
Cash from Investing+	102.58K	-6.64K	-11.89K	-41.43K	-19.35K	-15.6K	-22.91K	-31K	-21.02M	-38.53M
Capital Expenditures	-27.13K	-6.64K	-11.89K	-41.43K	-19.35K	-15.6K	-22.91K	-47K	-932.37K	-45.77K
CapEx % of Revenue	0.15%	0%	0%	0.3%	0%	0%	0.13%	0.01%	0.24%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-6.64K	-11.89K	-41.43K	0	0	0	16K	0	-38.49M
Cash from Financing+	25.72M	-8.53K	18.4M	8.01M	20.48M	52.68M	50.33M	76.04M	95.18M	-525.12K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-283.15K	-8.53K	1.44M	3.14M	-1.47M	9.59M	-2.43M	-3.83M	-4.83M	-254.46K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.34M	-8.51M	-7.79M	-15.33M	-10.86M	-17.66M	-30.25M	-35.93M	-35.75M	-62.1M
FCF Margin %	-64.76%	-2.02%	-2.96%	-109.66%	-1.45%	-4.57%	-177.57%	-10.25%	-9.31%	-12.31%
FCF Growth %	-0.45%	0.25%	0.09%	-0.97%	0.29%	-0.63%	-0.71%	-0.19%	0%	-0.74%
FCF per Share	-0.27	-0.20	-0.18	-0.36	-0.27	-0.29	-0.35	-0.40	-0.30	-0.43
FCF Conversion (FCF/Net Income)	0.18x	0.91x	0.61x	0.94x	0.80x	0.59x	0.94x	0.90x	0.82x	1.01x
Interest Paid	0	0	0	0	0	0	0	0	0	35.55K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-206.69%	-30.29%	-42.45%	-56.19%	-46.69%	-56.12%	-38.5%	-34.61%	-26.21%	-36.88%
Return on Invested Capital (ROIC)	-237.03%	-35.48%	-47.71%	-95.25%	-76.3%	-148.54%	-160.21%	-387.2%	-303.07%	-176.93%
Gross Margin	-3932.82%	59.69%	-279.77%	-11769.34%	-200.18%	-346.22%	-1111.18%	41.19%	-981.42%	-1117.55%
Net Margin	-35426.72%	-221.89%	-484.55%	-11640.01%	-179.9%	-774.12%	-18906.51%	-1138.04%	-1111.87%	-1218.02%
Debt / Equity	0.14x	0.22x	0.20x	0.31x	0.27x	0.04x	0.02x	0.01x	0.01x	0.01x
Interest Coverage	-7497.79x	-	-	-	-1531.88x	-3224.10x	-367.17x	-3808.07x	-2879.79x	-
FCF Conversion	0.18x	0.91x	0.61x	0.94x	0.80x	0.59x	0.94x	0.90x	0.82x	1.01x
Revenue Growth	-91.64%	2311.59%	-37.69%	-94.69%	5255.8%	-48.4%	-95.59%	1957.72%	9.59%	31.28%

Frequently Asked Questions

Growth & Financials

Immutep Limited (IMMP) reported $8.9M in revenue for fiscal year 2025. This represents a 485% increase from $1.5M in 2012.

Immutep Limited (IMMP) grew revenue by 31.3% over the past year. This is strong growth.

Immutep Limited (IMMP) reported a net loss of $104.2M for fiscal year 2025.

Dividend & Returns

Immutep Limited (IMMP) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.

Immutep Limited (IMMP) had negative free cash flow of $97.8M in fiscal year 2025, likely due to heavy capital investments.